|
業務類別
|
Biotechnology |
|
業務概覽
|
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261. |
| 公司地址
| 4000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080 |
| 電話號碼
| +1 650 822-5600 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.kezarlifesciences.com |
| 員工數量
| 55 |
| Mr. Marc L. Belsky |
Chief Financial Officer and Secretary |
美元 462.00K |
01/04/2025 |
| Ms. Pichi Pattie Chiang |
Principal Accounting Officer and Senior Vice President, Corporate Controller |
-- |
01/04/2025 |
| Mr. Mark C. Schiller |
Chief Legal Officer |
美元 451.00K |
25/04/2025 |
| Dr. Christopher Kirk, PhD |
Director and Chief Executive Officer |
美元 600.00K |
25/04/2025 |
|
|
| Mr. Franklin M. Berger, C.F.A. |
Independent Director |
25/04/2025 |
| Mr. Graham K. Cooper |
Chairman of the Board |
25/04/2025 |
| Dr. Michael Glen Kauffman, M.D.,PhD |
Independent Director |
25/04/2025 |
| Dr. Elizabeth Garner, M.D. |
Independent Director |
25/04/2025 |
| Mr. John Franklin Fowler |
Director |
25/04/2025 |
| Dr. Christopher Kirk, PhD |
Director and Chief Executive Officer |
25/04/2025 |
| Dr. Micki Klearman, M.D. |
Independent Director |
25/04/2025 |
| Ms. Courtney Wallace |
Independent Director |
25/04/2025 |
|
|
|
|
